314 related articles for article (PubMed ID: 35113367)
1. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.
Mhandire DZ; Goey AKL
Mol Diagn Ther; 2022 Mar; 26(2):137-151. PubMed ID: 35113367
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic testing in oncology: a Brazilian perspective.
Suarez-Kurtz G
Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e565s. PubMed ID: 30328952
[TBL] [Abstract][Full Text] [Related]
3. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
[TBL] [Abstract][Full Text] [Related]
4. PharmFrag: An Easy and Fast Multiplex Pharmacogenetics Assay to Simultaneously Analyze 9 Genetic Polymorphisms Involved in Response Variability of Anticancer Drugs.
Bouvet R; Verdier MC; El Baroudi Y; Galibert MD; David V; Schutz S; Tron C
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348915
[TBL] [Abstract][Full Text] [Related]
5. Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.
Hulshof EC; Deenen MJ; Guchelaar HJ; Gelderblom H
Eur J Cancer; 2020 Dec; 141():9-20. PubMed ID: 33125947
[TBL] [Abstract][Full Text] [Related]
6. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Texis T; Guzmán-Cruz C; Rodríguez-Dorantes M; Sánchez-García S; Mino-León D; Gonzalez-Covarrubias V
Pharmacol Rep; 2022 Feb; 74(1):257-262. PubMed ID: 34091879
[TBL] [Abstract][Full Text] [Related]
7. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
[TBL] [Abstract][Full Text] [Related]
9. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
[TBL] [Abstract][Full Text] [Related]
10. Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing
Varughese LA; Bhupathiraju M; Hoffecker G; Terek S; Harr M; Hakonarson H; Cambareri C; Marini J; Landgraf J; Chen J; Kanter G; Lau-Min KS; Massa RC; Damjanov N; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
Front Oncol; 2022; 12():859846. PubMed ID: 35865463
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
Quaranta S; Thomas F
Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
[TBL] [Abstract][Full Text] [Related]
12. Can pharmacogenetics help rescue drugs withdrawn from the market?
Shah RR
Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
[TBL] [Abstract][Full Text] [Related]
13. The contribution of pharmacogenetics to pharmacovigilance.
Bondon-Guitton E; Despas F; Becquemont L
Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
[TBL] [Abstract][Full Text] [Related]
14. Modern developments in germline pharmacogenomics for oncology prescribing.
Reizine NM; O'Donnell PH
CA Cancer J Clin; 2022 Jul; 72(4):315-332. PubMed ID: 35302652
[TBL] [Abstract][Full Text] [Related]
15. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
Hafner S; Haubensak S; Paul T; Zolk O
Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
[No Abstract] [Full Text] [Related]
16. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
Varughese LA; Lau-Min KS; Cambareri C; Damjanov N; Massa R; Reddy N; Oyer R; Teitelbaum U; Tuteja S
Pharmacotherapy; 2020 Nov; 40(11):1108-1129. PubMed ID: 32985005
[TBL] [Abstract][Full Text] [Related]
17. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Maitland ML; Vasisht K; Ratain MJ
Trends Pharmacol Sci; 2006 Aug; 27(8):432-7. PubMed ID: 16815558
[TBL] [Abstract][Full Text] [Related]
18. Ten-year experience with pharmacogenetic testing for
Bignucolo A; De Mattia E; Roncato R; Peruzzi E; Scarabel L; D'Andrea M; Sartor F; Toffoli G; Cecchin E
Front Pharmacol; 2023; 14():1199462. PubMed ID: 37256229
[No Abstract] [Full Text] [Related]
19. Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting.
Luczak TS; Schillo PJ; Renier CM; Waring SC; Friday BB
J Oncol Pharm Pract; 2022 Jun; 28(4):842-849. PubMed ID: 33853470
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.
Abdullah-Koolmees H; van Keulen AM; Nijenhuis M; Deneer VHM
Front Pharmacol; 2020; 11():595219. PubMed ID: 33568995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
